Stryker Corporation (SYK) has reported significant developments and predictions, including VP share sales and earnings call transcripts. Citi raised SYK's price target from $443 to $455 as FDA cleared Stryker's OptaBlate System. Stryker has also demonstrated robust and strategic growth in its quarterly results; Q1 2025 witnessed strong organic growth. Despite expectations of CEO compensation pauses, Citi reaffirmed the increased price target. Stryker's upcoming financial results for the first quarter of 2025 are highly anticipated. Stryker achieved FDA clearance for its OptaBlate BVN Basivertebral Nerve Ablation System and better-than-expected sales in Q4. However, the stock value might fall below $300. Stryker's leadership team is preparing to share strategic insights. The company has 79% institutional ownership, fueling the belief that Stryker remains a favorite among major investors. Its intrinsic value is under calculation as the company is on track to launch Mako Spine And Shoulder. Stryker’s Q1 surpassed revenue expectations while its shareholder meeting is going virtual. Despite introducing Next-Generation Mako SmartRobotics, the stocks fell. Inari Medical's acquisition has allowed Stryker to enter high-growth peripheral vascular sector. Tariff headwinds have affected Stryker alongside a $200 million tariff. Stryker's novel product, Sync Badge, has also been launched.
Stryker Corporation SYK News Analytics from Thu, 17 Oct 2024 07:00:00 GMT to Sat, 24 May 2025 20:10:45 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor -1
